AG Nominee Pam Bondi Confirms Commitment To Defending Constitutionality of False Claims Act as Qui Tam Provisions Face Scrutiny in the Courts
Client Alert | 2 min read | 01.16.25
Yesterday, less than an hour into the first day of confirmation hearings for attorney general nominee Pam Bondi, Senator Chuck Grassley (R-IA) questioned Bondi on her commitment to defending the constitutionality of the False Claims Act (FCA) if she is confirmed. Bondi responded that she would “of course” defend the constitutionality of the FCA and that she understands the importance of whistleblowers, the FCA’s protections, and “the money it brings back to our country.” Senator Grassley’s questioning indicated he was focused on the FCA’s qui tam provisions, as it comes on the heels of U.S. ex rel. Zafirov v. Florida Medical Associates, Inc., -- F.Supp.3d --, 2024 WL 4349242 (M.D. Fla. Sept. 30, 2024), a first-of-its-kind decision from Judge Kathryn Kimball Mizelle, who held that the FCA’s qui tam provisions improperly appoint a relator “an officer of the United States” in violation of the Appointments Clause in Article II of the Constitution, and are therefore unconstitutional. Senator Grassley appeared to be seeking assurances about Bondi’s willingness to ensure the Department of Justice continues to defend the FCA’s qui tam provisions and commit the resources necessary to do so.
Senator Grassley is the well-known architect of the 1986 Amendments to the FCA that overhauled the qui tam provisions and gave them renewed focus. According to Senator Grassley, through the 2024 Fiscal Year, the United States has recovered more than $78 billion from FCA actions, the majority of which came from qui tam actions brought by relators. The constitutionality of the qui tam provisions has been a simmering debate among FCA practitioners for many years but has enjoyed a renewed focus since Justice Thomas’s dissent in the Supreme Court’s decision in U.S. ex rel. Polansky v. Executive Health Resources, Inc., 599 U.S. 419 (2023), which identified what Justice Thomas called “substantial arguments” that the qui tam provisions are unconstitutional. The recent Zafirov decision, now on appeal before the Eleventh Circuit, may ultimately give the Supreme Court the opportunity to take up that issue.
While it remains unclear how the change in administration may affect the debate about the constitutionality of the qui tam provisions, the fact that Senator Grassley asked attorney general nominee Bondi about her willingness to defend their constitutionality so early in the hearing suggests that the importance of the question has not been lost on Congress. Assuming Bondi is confirmed by the Senate, which seems likely at this point, time will tell whether her statement yesterday holds during the coming administration.
Contacts
Insights
Client Alert | 5 min read | 08.21.26
FTC Proposes Enforcement Policy Statement on Personalized Pricing: What Businesses Need to Know
On August 19, 2026, the Federal Trade Commission (FTC) announced a proposed Enforcement Policy Statement on personalized pricing — the practice of companies using consumers’ personal data to set individualized prices, discounts, coupons, or other incentives. The proposed statement, which is open for public comment for 30 days following publication in the Federal Register, marks a major step up in the FTC’s focus on data-driven pricing strategies and puts businesses across industries on notice that undisclosed or inadequately disclosed personalized pricing will not be tolerated. Importantly, while the proposed statement is not a binding legal requirement and does not create new legal obligations, it serves as an enforcement warning that the FTC is prepared to use its existing enforcement authority under Section 5 of the FTC Act (Section 5) and is also a potential harbinger of rulemaking. Businesses that engage in — or are considering — personalized pricing should carefully assess their disclosure practices and data collection procedures against the standards articulated in this statement.
Client Alert | 7 min read | 08.19.26
CMS’s Final Rule Bans Federal Medicaid Funding for Youth Gender-Affirming Care
Client Alert | 2 min read | 08.19.26


